Stock Analiz

Accendra Health Inc. ACH

Medical Specialities · data as of November 13, 2026

$0.13Market cap $10M
Open the interactive analysis →

Accendra Health Inc. (ACH) is a healthcare company listed in the US with a market value of about $10M. In the twelve months to September 30, 2026 it had revenue of $2.6B and net income of -$172M, a net margin of -6.7%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is value (1/5); the weakest is future growth (0/5).

Key numbers: 5-year revenue growth of -20% a year, a 5-year average ROIC of 3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 725% above the current price.

About Accendra Health

Accendra Health is listed in the US and classified in medical specialities. Revenue went from $9.4B in 2014 to $2.8B in 2025, a decline of about 10.6% a year. It was profitable in 5 of the last 10 years in our data.

Score: 0.6 / 5

Value1/5
Future growth0/5
Track record1/5
Financial health0/5
Shareholder returns1/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • ROE above 15%
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.0
P/B—
EV/EBITDA7.8
PEG—
Dividend yield—
FCF yield-1961.0%
Shareholder yield100.2%
Intrinsic value vs. price+725%

Growth and quality

Revenue growth (1 yr)3.1%
Revenue growth (5 yrs, per year)-20.1%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-10.5%
ROIC (5-yr avg.)2.8%
Profitable years (of last 10)5
Years paying a dividend6

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$2.6B$2.8B$2.7B$2.6B$10.0B$9.8B$8.5B$9.2B$9.4B$9.3B$9.7B
Net income-$172M-$1.1B-$363M-$41M$22M$222M$30M-$62M-$437M$73M$109M
Free cash flow-$199M-$293M-$9M$568M$167M$83M$289M$124M$71M$22M$167M
EPS (diluted)$-2.25$-14.31$-4.73$-0.53$0.29$2.94$0.47$-1.03$-7.28$1.20$1.76
Net margin-6.7%-39.9%-13.5%-1.6%0.2%2.3%0.4%-0.7%-4.6%0.8%1.1%
ROIC—1.3%-6.7%2.3%3.0%14.1%8.6%2.6%-14.8%3.6%8.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Accendra Health stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 725% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Accendra Health pay a dividend?

Not currently.

Is Accendra Health a good stock to buy?

We do not give buy or sell advice. Accendra Health scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.